Amarin raises additional funds through over allotment to top $100M
This article was originally published in Scrip
Amarin Corporation has added an extra $13.7 million to the $87.1 million it raised on its 6 January public offering of American Depositary Shares (ADSs) after its underwriters exercised in full their options to purchase up to an aggregate of 1.8 million additional ADSs to cover over-allotments. The exercise of the over-allotment option increases the size of the offering to an aggregate of 13.8 million ADSs at a public offering price of $7.60 per ADS.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.